Alterity Therapeutics (NASDAQ:ATHE) Shares Down 3.8% – What’s Next?

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE)’s stock price was down 3.8% on Friday . The stock traded as low as $3.27 and last traded at $3.29. Approximately 17,147 shares traded hands during trading, an increase of 34% from the average daily volume of 12,767 shares. The stock had previously closed at $3.42.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alterity Therapeutics currently has a consensus rating of “Hold” and an average target price of $12.00.

Alterity Therapeutics Stock Performance

The firm has a 50-day simple moving average of $3.98 and a 200 day simple moving average of $4.45.

Institutional Trading of Alterity Therapeutics

Large investors have recently bought and sold shares of the business. Greenleaf Trust acquired a new position in Alterity Therapeutics in the second quarter valued at $70,000. Citadel Advisors LLC acquired a new position in Alterity Therapeutics in the 3rd quarter valued at about $83,000. HB Wealth Management LLC purchased a new stake in Alterity Therapeutics during the 3rd quarter valued at approximately $220,000. Finally, Twin Lakes Capital Management LLC raised its stake in Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after acquiring an additional 133,333 shares during the last quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.